Amedisys (NASDAQ:AMED) Releases Earnings Results, Beats Expectations By $0.01 EPS

Amedisys (NASDAQ:AMED) announced its quarterly earnings results on Wednesday. The health services provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01, Briefing.com reports. Amedisys had a positive return on equity of 13.00% and a negative net margin of 0.91%. The company had revenue of $571.41 million during the quarter, compared to analysts’ expectations of $565.38 million. During the same period in the prior year, the business posted $1.00 EPS. Amedisys’s revenue was up 2.7% on a year-over-year basis.

Amedisys Trading Up 0.5 %

Shares of NASDAQ:AMED traded up $0.50 during midday trading on Friday, hitting $91.66. 39,873 shares of the stock were exchanged, compared to its average volume of 274,900. The stock has a market capitalization of $2.99 billion, a price-to-earnings ratio of -142.84, a P/E/G ratio of 4.28 and a beta of 0.86. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.05 and a current ratio of 1.05. The business’s 50-day moving average price is $92.57 and its 200 day moving average price is $93.35. Amedisys has a 12 month low of $73.10 and a 12 month high of $96.44.

Analysts Set New Price Targets

AMED has been the subject of several research reports. StockNews.com initiated coverage on shares of Amedisys in a research note on Monday, April 8th. They set a “buy” rating for the company. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $101.00 price target on shares of Amedisys in a research note on Thursday. Raymond James reaffirmed a “market perform” rating on shares of Amedisys in a research note on Tuesday, March 26th. Finally, Royal Bank of Canada increased their price objective on Amedisys from $97.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, March 25th. Seven analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $97.50.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.